Epithalon (Epitalon)

Epithalon (also spelled Epitalon; the peptide AEDG) is the synthetic tetrapeptide L-alanyl-L-glutamyl-L-aspartyl-glycine. It was designed in St Petersburg by Vladimir Khavinson's group at the Institute of Bioregulation and Gerontology as a defined-sequence substitute for epithalamin, a polypeptide extract of bovine pineal gland that had been used in Soviet and Russian geriatric medicine since the 1980s. The claim that made the peptide famous — that it switches on telomerase in normal human cells — comes from that group's own laboratory, and the structure of the evidence base is the first thing a researcher should understand about the compound.

The Khavinson-group telomerase findings

In 2003, Khavinson, Bondarev and Butyugov reported in the Bulletin of Experimental Biology and Medicine that adding Epithalon to cultures of telomerase-negative human fetal fibroblasts induced expression of the telomerase catalytic subunit, measurable telomerase enzymatic activity, and telomere elongation [1]. A 2004 follow-up used primary fetal lung fibroblasts that had reached replicative senescence at passage 34 with shortened telomeres; peptide treatment elongated the telomeres to lengths comparable with passage 10 and the cells completed ten additional divisions, to passage 44, and were still dividing at the time of the report. The authors described this as overcoming the Hayflick limit [2]. These are short communications with limited methodological detail by present standards, and the journal in which they appeared is the English translation of a Russian journal on whose editorial board the senior author sat.

Mouse lifespan and the human extract data

Anisimov et al. (2003) treated 54 female outbred SHR mice with 1 µg of Epitalon on five consecutive days each month from age 3 months until death, against 54 saline controls. Epitalon did not change food intake, body weight or mean lifespan. It slowed the age-related loss of oestrous cycling, reduced bone-marrow chromosome aberrations by 17.1%, and extended the lifespan of the last 10% of survivors by 13.3% and maximum lifespan by 12.3%. Total tumour incidence was unchanged but leukaemia incidence was six-fold lower [3]. The much-cited “15-year follow-up” from Korkushko et al. (2011) is often attributed to Epithalon but concerns epithalamin, the pineal extract: 39 coronary patients received six courses over three years alongside standard therapy versus 40 on standard therapy alone, with the authors reporting slower cardiovascular ageing, preserved physical endurance, normalised melatonin rhythm and lower mortality [4]. That study is small, open-label, and about a different preparation.

The independence problem, stated plainly

For roughly two decades, essentially every publication on AEDG came from the Khavinson group or its collaborators, and most appeared in Russian-language journals or their translations. Publication in a single laboratory's house journals is not evidence of fraud, but it means the central claim had never passed the ordinary test of replication by a group with no stake in the result. That has started to change. In 2022, a Shanxi Medical University group reported that 0.1 mM Epitalon added to culture medium reduced reactive oxygen species, spindle defects and cortical-granule abnormalities in post-ovulatory ageing mouse oocytes over 24 hours, with higher mitochondrial membrane potential and less apoptosis; they framed the peptide as an antioxidant, not a telomerase activator [5]. In 2025, Al-Dulaimi and colleagues at Brunel University London published the first independent telomere study in Biogerontology: in normal human epithelial and fibroblast cells, Epitalon produced dose-dependent telomere lengthening with upregulation of hTERT mRNA and telomerase activity, while in the breast-cancer lines 21NT and BT474 telomere extension occurred instead through the alternative lengthening of telomeres (ALT) pathway [6]. A correction to that paper was issued in November 2025. The Brunel result is broadly consistent with the 2003 claim, and it is one study.

What the research does not establish

No controlled human trial of the AEDG tetrapeptide has been published; the human data are for the pineal extract [4]. The mouse study extended maximum, not mean, lifespan in one strain and one sex [3]. Telomerase induction has been shown in cultured cells only [1][2][6], and the same 2025 study found that Epitalon extended telomeres in cancer cells via ALT [6], a reminder that anything which lengthens telomeres in normal cells warrants equal scrutiny for what it does in transformed ones. Mechanism is unresolved: proposals range from direct DNA binding at promoter sites to antioxidant action [5], and none is established. Whether an orally or parenterally administered tetrapeptide survives to reach a cell nucleus intact is also not demonstrated. This material is supplied strictly for in-vitro laboratory research.

Format. Lyophilized powder in a sealed glass vial. Stated mass refers to the tetrapeptide (acetate salt).

Reconstitution. Reconstitute with sterile or bacteriostatic water, directing the stream against the glass wall and swirling gently until dissolved. The peptide is small, acidic (two carboxylate side chains plus the C-terminus) and freely water-soluble. Our reconstitution calculator converts vial mass and diluent volume into concentration and U-100 syringe units.

Storage. Lyophilized vials are typically stored at −20 °C and protected from light. Reconstituted solutions are generally refrigerated at 2–8 °C. The Asp-Gly bond is a classic site for aspartimide formation and isomerisation in solution, so long-stored solutions may contain iso-aspartyl species; aliquot before freezing and avoid repeated freeze-thaw cycles.

Handling. Standard laboratory practice applies: appropriate PPE, aseptic technique when reconstituting, and disposal in line with your institution's procedures. For in-vitro laboratory research only — not for human or veterinary use.